Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q4 2020 Results - Earnings Call Transcript

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of -12.24% and 1.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

CoDiagnostics, Inc. (CODX) Q4 Earnings Lag Estimates

Co-Diagnostics Inc (NASDAQ:CODX) announced Thursday that it earned a net income of $42.5 million in 2020 as its Logix Smart coronavirus (COVID-19) test drove record sales.  That's a huge turnaround for the Utah-based molecular diagnostics company which posted a $5.6 million loss in 2019.

Co-Diagnostics posts 2020 net income of $42.5M as its Logix Smart COVID-19 test drove record sales

Shares of Co-Diagnostics (NASDAQ:CODX) moved lower in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 577.78% year over year to $0.43, which missed the estimate of $0.48.

Recap: Co-Diagnostics Q4 Earnings

SALT LAKE CITY, March 25, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the fourth quarter and full year ended December 31, 2020. Fourth Quarter 2020 Financial Results: Revenue of $27.1 million, primarily due to sales of the Logix Smart™ COVID-19 Test Gross profit increased to $22.8 million, representing 84.1% of consolidated revenue due to improved product mix as compared to the prior-year period Operating income improved to $16.0 million, due to record revenue and gross profit Income before taxes of $15.8 million Net income of $12.8 million, compared to a net loss of $1.7 million in the prior-year fourth quarter, representing $0.43 per fully diluted share Full Year 2020 Financial Results: Revenue of $74.6 million, an increase of $74.3 million, primarily due to sales of Logix Smart COVID-19 Tests throughout the world Gross profit increased to $58.0 million, representing 77.7% of consolidated revenue Operating income improved to $41.7 million due to record revenue and gross profit for the year Income before taxes of $42.6 million Net income of $42.5 million, compared to a loss of $5.6 million from the prior year, representing $1.52 per fully diluted share, and reflecting a full utilization of historical net operating losses Cash, cash equivalents, and marketable securities totaled $47.3 million as of December 31, 2020, an increase of $46.4 million from December 31, 2019 "This year marked a critical inflection point in our ability to establish Co-Diagnostics as a leading global molecular diagnostic company, driving innovation through our proprietary technologies across the infectious disease market," said Dwight Egan, Co-Diagnostics' Chief Executive Officer.

Co-Diagnostics Reports Fourth-Quarter and Full-Year 2020 Financial Results

CODX stock's true value isn't fully appreciated by the investing community, and this could provide a setup for an explosive move. The post Co-Diagnostics Stock Is an Out-and-Out Buy Before the Earnings Release appeared first on InvestorPlace.

Co-Diagnostics Stock Is an Out-and-Out Buy Before the Earnings Release

SALT LAKE CITY, March 18, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth-quarter and full-year 2020 results on March 25, 2021, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Co-Diagnostics, Inc. Announces Fourth-Quarter and Full-Year 2020 Earnings Release Date and Webcast

SALT LAKE CITY, March 16, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has been invited to present at the Maxim Group LLC and M Vest LLC Inaugural Emerging Growth Virtual Conference, held virtually March 17-18, 2021. The Company's presentation is expected to include a discussion of its at-home and point-of-care rapid PCR diagnostics platform currently in development, as the platform relates to supporting COVID-19 testing initiatives at the places where interactions take place to help normalize work, school, home and travel routines.

Co-Diagnostics Invited to Present at Maxim Group LLC Emerging Growth Virtual Conference

Co-Diagnostics went public in 2017 with a proprietary infectious disease testing technology and a clever strategy. During its early rollout, Co-Diagnostics' strategy failed to generate noticeable revenues.

Co-Diagnostics: A+ Student Faces New Tests

Fulgent Genetics

Johnson & Johnson

Moderna

Novavax

2020 was a wild run for the biotech sector, with COVID-19 dominating the headlines. What will happen this year?

Biotech Stocks: What Will 2021 Look Like?

SALT LAKE CITY, March 10, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will be presenting at the 2nd Annual MarketsandMarkets Infectious Disease Diagnostics and Point-Of-Care Testing Virtual Conference, held March 11-12, 2021. The Conference website states that the event will serve as a networking place for diagnostics professionals, industry specialists, and solution providers to address the rising innovation in point-of-care testing and the way it can be used as a disease prevention tool.

Co-Diagnostics to Present Point-of-Care and At Home Testing Platform at Infectious Disease Diagnostics Virtual Conference

SALT LAKE CITY, March 8, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will present at the 2021 H....

Co-Diagnostics to Discuss Recent Company Advances at H.C. Wainwright Global Life Sciences Virtual Conference

Applied Genetic Technologies

Atomera

Aytu BioScience

Cortexyme Inc

Dynavax Technologies

Sorrento Therapeutics

Getting a big headache watching large-cap S&P 500 stocks lose steam? Small-cap stocks are giving investors a new way to make big money.

7 Small Stocks Up Big Can Still Double From Here, Analysts Say

Co-Diagnostics Inc (NASDAQ:CODX) has announced the development of a new at-home PCR-based coronavirus (COVID-19) testing, screening and surveillance platform that delivers rapid results via smartphone. The small cube-shaped device is designed to perform COVID-19 testing at businesses, schools, homes, hotels, cruise ships, airports, airplanes and other locations.

Co-Diagnostics is designing at-home coronavirus PCR saliva test delivering results by smartphone app

Co-Diagnostics designs at-home coronavirus PCR saliva test delivering results by smartphone app

Walgreens

Co-Diagnostics Inc (NASDAQ:CODX) has confirmed that its patented CoPrimer technology is part of a coronavirus (COVID-19) saliva test that is now available through Walgreens Find Care, a digital health platform on the retailer's website and mobile app. In a statement on Thursday, Dwight Egan, Co-Diagnostics CEO commented: “Co-Diagnostics is proud that our technology will be available on an even more widespread basis following this announcement by our trusted partner CRL, one of the largest privately-held clinical testing laboratories in the U.S.

Co-Diagnostics notes its CoPrimer technology powers coronavirus saliva test now available through Walgreens digital health platform

Its technology underpins a coronavirus test that's about to get much wider distribution.

Why Co-Diagnostics Stock Is Shooting Higher Today

Co-Diagnostics Inc (NASDAQ:CODX) patented CoPrimer technology is part of a coronavirus (COVID-19) saliva test that is now available through Walgreens Find Care, a digital health platform on the retailer's website and mobile app.  The company's COVID-19 RT-PCR test is being sold by Clinical Reference Laboratory under its CRL HealthConfirm brand name for $119 per kit, according to a CRL statement released Wednesday.

Co-Diagnostics' CoPrimer technology powers coronavirus saliva test now available through Walgreens digital health platform

With the latter appointment, the company's founder moves into a more advisory role.

Co-Diagnostics Names New CFO and CSO

Co-Diagnostics Inc (NASDAQ:CODX) announced Tuesday the appointment of Brian Brown as the company's new chief financial officer (CFO). The company said Brown's previous experience includes CFO, vice president of accounting and investor relations, and director of finance roles for public and private companies.

Co-Diagnostics appoints long-time executive Brian Brown as its new chief financial officer

SALT LAKE CITY, Feb. 23, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it is pleased to welcome Brian Brown, CPA to the position of Co-Diagnostics...

Co-Diagnostics, Inc. Announces New Chief Financial Officer

Co-Diagnostics Inc (NASDAQ:CODX) has said it will be presenting on direct saliva testing for coronavirus (COVID-19) at the 28th Annual International Molecular Medicine Tri-Conference, to be held virtually between February 16-18, 2021. Representatives of the molecular diagnostics specialist will introduce the Co-Diagnostics Logix Smart SARS-CoV-2 DS (Direct Saliva) kit, which the company has submitted for Emergency Use Authorization (EUA) to the US Food and Drug Administration (FDA).

Co-Diagnostics to present on direct saliva testing at Molecular Medicine Tri-Conference

The stock price of Co-Diagnostics Inc (NASDAQ: CODX) is up over 80% over the past month. This is why it happened.

CODX Stock Price Increased Over 80% This Past Month: Why It Happened

The good news is that the end of the pandemic is in sight. The bad news is that it may never really be over.

The Big Picture for Virus Testing Stocks (NASDAQ: FLGT) (OTC US: ALST) (NASDAQ: CODX)

This diagnostic specialist started off the year as a micro cap, but it roared ahead with its COVID-19 test.

News for Co-Diagnostics Stock (CODX)